NeuroBo Pharmaceuticals NRBO Stock
NeuroBo Pharmaceuticals Price Chart
NeuroBo Pharmaceuticals NRBO Financial and Trading Overview
| NeuroBo Pharmaceuticals stock price | 3.61 USD |
| Previous Close | 0.48 USD |
| Open | 0.5 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 800 |
| Day's Range | 0.47 - 0.5 USD |
| 52 Week Range | 0.47 - 63.85 USD |
| Volume | 139.09K USD |
| Avg. Volume | 369.12K USD |
| Market Cap | 13.45M USD |
| Beta (5Y Monthly) | -0.77771 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.46 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6 USD |
NRBO Valuation Measures
| Enterprise Value | -17736992 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.86649126 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.6541722 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 1.605 |
Trading Information
NeuroBo Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | -0.77771 |
| 52-Week Change | -96.10% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 63.85 USD |
| 52 Week Low | 0.47 USD |
| 50-Day Moving Average | 0.61 USD |
| 200-Day Moving Average | 3.6 USD |
NRBO Share Statistics
| Avg. Volume (3 month) | 369.12K USD |
| Avg. Daily Volume (10-Days) | 196.07K USD |
| Shares Outstanding | 27.24M |
| Float | 25.94M |
| Short Ratio | 0.79 |
| % Held by Insiders | 50.47% |
| % Held by Institutions | 5.88% |
| Shares Short | 237.41K |
| Short % of Float | 1.62% |
| Short % of Shares Outstanding | 0.86% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.76% |
| Return on Equity (ttm) | -84.44% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -11054000 USD |
| Net Income Avi to Common (ttm) | -13696000 USD |
| Diluted EPS (ttm) | -14.99 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 30.81M USD |
| Total Cash Per Share (mrq) | 1.13 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.867 |
| Book Value Per Share (mrq) | 0.755 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -9430000 USD |
| Levered Free Cash Flow (ttm) | 5.03M USD |
Profile of NeuroBo Pharmaceuticals
| Country | United States |
| State | MA |
| City | Boston |
| Address | 200 Berkeley Street |
| ZIP | 02116 |
| Phone | 857 702 9600 |
| Website | https://www.neurobopharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 2 |
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Q&A For NeuroBo Pharmaceuticals Stock
What is a current NRBO stock price?
NeuroBo Pharmaceuticals NRBO stock price today per share is 3.61 USD.
How to purchase NeuroBo Pharmaceuticals stock?
You can buy NRBO shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NeuroBo Pharmaceuticals?
The stock symbol or ticker of NeuroBo Pharmaceuticals is NRBO.
Which industry does the NeuroBo Pharmaceuticals company belong to?
The NeuroBo Pharmaceuticals industry is Biotechnology.
How many shares does NeuroBo Pharmaceuticals have in circulation?
The max supply of NeuroBo Pharmaceuticals shares is 4.91M.
What is NeuroBo Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
NeuroBo Pharmaceuticals PE Ratio is now.
What was NeuroBo Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
NeuroBo Pharmaceuticals EPS is -2.46 USD over the trailing 12 months.
Which sector does the NeuroBo Pharmaceuticals company belong to?
The NeuroBo Pharmaceuticals sector is Healthcare.
NeuroBo Pharmaceuticals NRBO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}